Appraisal of the role of the 68Ga-DOTANOC in the diagnostic by Positron emission tomography (PET) in the study of human tumors of neuroendocrine derivation - ND
- Conditions
- tumors of neuroendocrine derivationMedDRA version: 6.1Level: HLGTClassification code 10029112
- Registration Number
- EUCTR2006-001614-33-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Adult subjects (age >18 years) of both sex bearers of tumors of neuroendocrine derivation, joints for specialized appraisal to the Policlinico S.Orsola-Malpighi.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
subjects not in a position to meaning and of wanting, the healthy volunteers, the minors, the women in state of pregnancy, the women during breast-feeding, and patients in emergency situations.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: earlier diagnosis of the tumors of neuroendocrine derivation;Secondary Objective: therapeutic program personalized for every patient and therefore to reduce the charitable costs;Primary end point(s): to verify the additional role of the PET with 68Ga-DOTANOC in the diagnosis, stage and appraisal of the answer to the therapy and in the programming of an eventual aimed local x-ray, in patients affections from neoplasie of neuroendocrine derivation regarding the other techniques of diagnostic currently routinariamente used
- Secondary Outcome Measures
Name Time Method